Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering

Core Viewpoint - Aptose Biosciences Inc. has successfully closed a public offering, raising $8 million through the sale of 40 million common shares at $0.20 each, along with warrants for an additional 20 million shares [1]. Group 1: Offering Details - The public offering included 40,000,000 common shares priced at $0.20 per share and warrants to purchase up to 20,000,000 common shares at an exercise price of $0.25 per share, which are exercisable immediately and will expire in five years [1]. - The offering was conducted by A.G.P./Alliance Global Partners as the sole placement agent [2]. - The gross proceeds from the offering amounted to $8 million before deducting fees and expenses [1]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for working capital and general corporate purposes [1]. Group 3: Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [5]. - The company's lead product, tuspetinib (TUS), is an oral kinase inhibitor that has shown efficacy as both a monotherapy and in combination therapy for patients with relapsed or refractory acute myeloid leukemia (AML) [5].